Cerebellar Ataxia
Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)
Subtype terms (1)
More specific conditions that are subtypes of Cerebellar Ataxia in the MeSH hierarchy.
- Spinocerebellar Ataxias
14 drugs (6 approved, 8 experimental)
Drugs by status
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (22)
- Horizon Pharma
- Santhera
- Pfizer
- Cognitive Research Corporation
- Erydel
- PTC Therapeutics
- Retrotope, Inc.
- National Institutes of Health (NIH)
- University of Roma La Sapienza
- University of Pennsylvania
- University of London
- Federal University of Rio Grande do Sul
- University of South Florida
- University of California, Los Angeles
- University of California, San Francisco
- National Taiwan University
- University of Paris
- Agenzia Italiana del Farmaco
- Biohaven Pharmaceuticals Inc.
- Cytel Inc.
- Friedreich's Ataxia Research Alliance (FARA)
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (45)
- AbbVie
- Vidara Therapeutics
- Takeda
- Apotex
- Ipsen
- Baxalta
- Bioelectron
- Penwest Pharmaceuticals Co.
- Reata Pharmaceuticals, Inc.
- Sclnow Biotechnology Co., Ltd.
- Steminent Biotherapeutics Inc.
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- National Institute of Neurological Disorders and Stroke (NINDS)
- Central South University
- IRCCS Eugenio Medea
- McMaster University
- Nanjing Medical University
- Nanjing University
- National Yang-Ming University
- Radboud University
- RWTH Aachen University
- Seoul National University
- University of Melbourne
- University of Rochester
- University of Rome Tor Vergata
- Xuzhou Medical University
- Mayo Clinic
- University of California, Davis
- University of Naples Frederico II
- University of Queensland
- +15 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (3)